At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
In Brief
A Phase 3 clinical trial evaluating Letrozole, Paclitaxel, and 6 other interventions for Borderline Ovarian Serous Tumor and 5 related conditions. Completed, enrolled 260 participants across 501 sites in 2 countries.
Detailed Summary
This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
Study Details
Timeline
Interventions
Given PO
Given IV
Given IV
Ancillary studies
Ancillary studies
Given PO
Given IV
Given PO